Universe Pharmaceuticals (UPC) Competitors $3.52 -0.02 (-0.42%) Closing price 08/1/2025 03:58 PM EasternExtended Trading$3.52 0.00 (0.00%) As of 08/1/2025 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock UPC vs. HEPA, BPTSY, VIRX, NCNA, MYMD, SYRS, CAPS, VINC, BON, and VRPXShould you be buying Universe Pharmaceuticals stock or one of its competitors? The main competitors of Universe Pharmaceuticals include Hepion Pharmaceuticals (HEPA), Biophytis (BPTSY), Viracta Therapeutics (VIRX), NuCana (NCNA), MyMD Pharmaceuticals (MYMD), Syros Pharmaceuticals (SYRS), Capstone Therapeutics (CAPS), Vincerx Pharma (VINC), Bon Natural Life (BON), and Virpax Pharmaceuticals (VRPX). These companies are all part of the "pharmaceutical products" industry. Universe Pharmaceuticals vs. Its Competitors Hepion Pharmaceuticals Biophytis Viracta Therapeutics NuCana MyMD Pharmaceuticals Syros Pharmaceuticals Capstone Therapeutics Vincerx Pharma Bon Natural Life Virpax Pharmaceuticals Universe Pharmaceuticals (NYSE:UPC) and Hepion Pharmaceuticals (NASDAQ:HEPA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, profitability, institutional ownership, media sentiment and earnings. Which has more volatility and risk, UPC or HEPA? Universe Pharmaceuticals has a beta of 1.43, indicating that its stock price is 43% more volatile than the S&P 500. Comparatively, Hepion Pharmaceuticals has a beta of 1.69, indicating that its stock price is 69% more volatile than the S&P 500. Is UPC or HEPA more profitable? Universe Pharmaceuticals' return on equity of 0.00% beat Hepion Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Universe PharmaceuticalsN/A N/A N/A Hepion Pharmaceuticals N/A -812.56%-207.31% Which has preferable earnings & valuation, UPC or HEPA? Universe Pharmaceuticals has higher revenue and earnings than Hepion Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioUniverse Pharmaceuticals$19.29M0.01-$6.16MN/AN/AHepion PharmaceuticalsN/AN/A-$48.93M-$219.000.00 Do insiders & institutionals believe in UPC or HEPA? 0.2% of Universe Pharmaceuticals shares are held by institutional investors. Comparatively, 17.2% of Hepion Pharmaceuticals shares are held by institutional investors. 57.4% of Universe Pharmaceuticals shares are held by insiders. Comparatively, 0.1% of Hepion Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Does the media favor UPC or HEPA? In the previous week, Universe Pharmaceuticals' average media sentiment score of 0.00 equaled Hepion Pharmaceuticals'average media sentiment score. Company Overall Sentiment Universe Pharmaceuticals Neutral Hepion Pharmaceuticals Neutral SummaryUniverse Pharmaceuticals beats Hepion Pharmaceuticals on 5 of the 7 factors compared between the two stocks. Get Universe Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for UPC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding UPC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart UPC vs. The Competition Export to ExcelMetricUniverse PharmaceuticalsPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$152K$785.88M$5.48B$20.63BDividend YieldN/A4.84%4.73%3.67%P/E RatioN/A1.3728.8629.01Price / Sales0.0125.68371.7266.07Price / CashN/A19.5635.4522.82Price / Book0.026.758.274.43Net Income-$6.16M-$3.67M$3.25B$993.74M7 Day Performance-8.20%-4.92%-3.73%-3.39%1 Month Performance-7.72%-0.41%4.29%-2.10%1 Year Performance-99.84%15.62%25.87%10.09% Universe Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)UPCUniverse PharmaceuticalsN/A$3.53-0.4%N/A-99.8%$152K$19.29M0.00220Gap UpHEPAHepion Pharmaceuticals0.5024 of 5 stars$0.05-12.2%N/A-99.9%$696KN/A-0.0120Gap UpBPTSYBiophytisN/A$1.81flatN/AN/A$634KN/A0.0030VIRXViracta Therapeutics1.7269 of 5 stars$0.01flat$1.75+17,793.7%N/A$389KN/A-0.0120Short Interest ↑NCNANuCana2.6792 of 5 stars$0.06-7.7%$25.00+45,354.5%-98.9%$360KN/A-0.0130News CoverageShort Interest ↑MYMDMyMD PharmaceuticalsN/A$0.12-11.5%N/A-94.6%$277KN/A0.006Gap DownHigh Trading VolumeSYRSSyros Pharmaceuticals4.0223 of 5 stars$0.01-50.0%$3.33+33,233.3%-100.0%$268K$386K0.00120Gap DownCAPSCapstone TherapeuticsN/A$1.56-2.2%N/AN/A$250K$44.88M0.0038Positive NewsVINCVincerx Pharma2.5151 of 5 stars$0.05+0.4%$40.00+86,480.1%-99.7%$241KN/A0.0060Gap UpBONBon Natural LifeN/A$1.40+1.4%N/A-97.6%$234K$23.84M0.00100VRPXVirpax PharmaceuticalsN/A$0.06+164.3%N/A-100.0%$69KN/A0.007Gap Up Related Companies and Tools Related Companies HEPA Alternatives BPTSY Alternatives VIRX Alternatives NCNA Alternatives MYMD Alternatives SYRS Alternatives CAPS Alternatives VINC Alternatives BON Alternatives VRPX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:UPC) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersWhy Elon put $51 million into thisA single U.S. company has started producing a “miracle metal” once locked in research labs. Now? They’re qu...True Market Insiders | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Universe Pharmaceuticals INC Please log in to your account or sign up in order to add this asset to your watchlist. Share Universe Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
